All stock lists
Nexgel, Inc. (NASDAQ:NXGL)
US · Delayed Price · Currency is USD
Healthcare · Medical - Instruments & Supplies
$3.88+$0.09 (+2.37%)
Market cap
$1.89M
Insider Score
Health Score
Analyst consensus
Listed since
Dec 22, 2021
Website
Insider Score
68/ 100
NXGL Insider Score
Bullish2 qualifying trades · 2 insiders · $757.69K bought in the last 90 days
Financial Health Score
Distressed
From NXGL’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $12.1M
- Net income
- -$6.2M
- Net margin
- -51.3%
Leverage5 / 20
Heavily indebted for what it earns.
- Total debt
- $7.5M
- Cash
- $492K
- Debt / equity
- 1.51
Liquidity0 / 20
Owes more within a year than it holds to pay it.
- Current assets
- $6.2M
- Current liabilities
- $14.4M
- Current ratio
- 0.43
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$3.2M
- Free cash flow
- -$3.3M
- FCF margin
- -27.1%
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 0.5M
- Share growth (1y)
- 22.0%
- Cash runway
- 2 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NXGL Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | $3.69 M | $2.65 M | $2.80 M | $2.93 M | $2.88 M | $2.81 M |
| Revenue Growth (YoY) | 27.81 % | -5.56 % | -8.06 % | -0.20 % | 100.28 % | 121.64 % |
| Cost of Revenue | $2.58 M | $1.59 M | $1.98 M | $1.69 M | $1.63 M | $1.62 M |
| Gross Profit | $1.11 M | $1.06 M | $819.00 K | $1.24 M | $1.26 M | $1.19 M |
| SG&A Expense | $3.59 M | $2.02 M | $2.03 M | $1.88 M | $1.82 M | $1.89 M |
| R&D Expense | $20.00 K | $0.00 | $0.00 | $7.00 K | $0.00 | $1.00 K |
| Operating Expenses | $3.61 M | $2.02 M | $2.03 M | $1.97 M | $1.89 M | $1.97 M |
| Operating Income | -$2.50 M | -$958.00 K | -$1.21 M | -$725.00 K | -$636.00 K | -$777.00 K |
| Pretax Income | -$3.61 M | -$871.00 K | -$928.00 K | -$647.00 K | -$640.00 K | -$678.00 K |
| Tax Provision | $0.00 | $56.00 K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$3.63 M | -$927.00 K | -$970.00 K | -$653.00 K | -$665.00 K | -$712.00 K |
| EPS (Basic) | -$8.07 | -$2.26 | -$2.38 | -$1.64 | -$1.74 | -$1.86 |
| EPS (Diluted) | -$8.07 | -$2.26 | -$2.41 | -$1.64 | -$1.80 | -$1.86 |
| Shares Outstanding | 450.66 K | 410.21 K | 401.83 K | 398.56 K | 369.44 K | 382.27 K |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.